501939-95-3

Upstream product

• 519003-01-1 (5R)-5-(azidomethyl)-3-(3-fluoro-4-iodophenyl)-1,3-oxazolidin-2-one 
• 121-46-0 bicyclo[2.2.1]hepta-2,5-diene 
• 916888-23-8 (5R)-3-(3-fluoro-4-iodo-phenyl)-5-(4-trimethylsilanyl-[1,2,3]triazol-1-ylmethyl)-oxazolidin-2-one 
• 501939-82-8 (5R)-methanesulfonic acid 3-(3-fluoro-4-iodophenyl)-2-oxo-oxazolidin-5-ylmethyl ester 
• 149524-42-5 (5R)-3-(3-fluorophenyl)-5-hydroxymethyloxazolidin-2-one 
• 487041-08-7 (5R)-3-(3-fluoro-4-iodo-phenyl)-5-hydroxymethyl-1,3-oxazolidin-2-one 
• 1066-54-2 trimethylsilylacetylene 

Downstream Products

• 700370-33-8 (5R)-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 
• 700370-34-9 (R)-(4-(5-((1H-1,2,3-triazol-1-yl)methyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)boronic acid 
• 698981-84-9 (5R)-3-{4'-[5-({[tert-butyl(dimethyl)silyl]oxy}methyl)-4,5-dihydroisoxazol-3-yl]-2-fluoro-3`-methoxy-1,1`-biphenyl-4-yl}-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 
• 698981-94-1 (5R)-3-{4`-[5-({[tert-butyl(dimethyl)silyl]oxv}methyl)-4,5-dihydroisoxazol-3-yl]-2,3`-difluoro-1,1`-binhenyl-4-yl}-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 
• 1202701-57-2 C<sub>19</sub>H<sub>16</sub>FN<sub>7</sub>O<sub>2</sub> 
• 698981-89-4 (5R)-3-{2-fluoro-4`-[5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]-3`-methoxy-1,1`-biphenyl-4-yl}-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 
• 702681-58-1 (5R)-3-{3-fluoro-4-[6-((5S)-5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl)pyridin-3-yl]phenyl}-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 

Relevant academic research and scientific papers

Process for the synthesis of triazoles

The present invention relates to processes for the preparation of triazoles. These compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents.

BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME

The present invention relates generally to the field of anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. More particularly, the invention relates to a family of tricyclic compounds that are useful as such agents.

3-[4-(6-{4,5-DIHYDROISOXAZOL-3-YL}PYRIDIN-3-YL)-3-PHENYL]-5-(1H-1,2,3-TRIAZOL-1-YLMETHYL)-1,3-OXAZOLIDIN-2-ONES AS ANTIBACTERIAL AGENTS

Compounds of the formula (I): or a pharmaceutically- acceptable salt or pro-drug thereof: wherein R1 is selected for example from hydrogen, halogen, optionally substituted methyl; R2 and R3 are independently selected from

3- `4- {6-SUBSTITUTED ALKANOYL) PYRIDIN-3-YL} -3-PHENYL! -5- (1H-1, 2, 3-TRIAZOL-1-YLMETHYL) -1, 3-OXAZOLIDIN-2-ONES AS ANTIBACTERIAL AGENTS

Compounds of formula (I) as well as pharmaceutically-acceptable salts and pro-drugs thereof are disclosed wherein R1, R2, R3, and R4 are defined herein. Also disclosed are processes for making compounds of formula (I) as well as methods of using compounds of formula (I) for treating bacterial infections.

3- {4- (PYRIDIN-3-YL) PHENYL} -5- (1H-1, 2, 3-TRIAZOL-1-YLMETHYL) -1, 3-OXAZOLIDIN-2-ONES AS ANTIBACTERIAL AGENTS

Compounds of formula (I), as well as pharmaceutically-acceptable salts and pro-drugs thereof, are disclosed wherein R1, R2, R3, and R4 are defined herein. Also disclosed are processes for making compounds of formula (I) as well as methods of using compounds of formula (I) for treating bacterial infections.

3- (4- (2-DIHYDROISOXAZOL-3-YLPYRIDIN-5-YL) PHENYL) -5-TRIAZOL-1-YLMETHYLOXAZOLIDIN-2-ONE DERIVAIVES AS MAO INHIBITORS FOR THE TREATMENT OF BACTERIAL INFECTIONS

Compounds of formula (I) as well as pharmaceutically-acceptable salts and pro-drugs thereof are disclosed wherein R1, R2, R3, and R4 are defined herein. Also disclosed are processes for making compounds of formu

OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF

This invention relates to new oxazolidinones having a cyclopropyl moiety, which are effective against aerobic and anerobic pathogens such as multi-resistant staphylococci, streptococci and enterococci, Bacteroides spp., Clostridia spp. Species, as well as acid-fast organisms such as Mycobacterium tuberculosis and other mycobacterial species. The compounds are represented by structural formula: (I); its enantiomer, diastereomer, or pharmaceutically acceptable salt or ester thereof.

ANTIBACTERIAL COMPOUNDS

A compound of the formula (I), or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof wherein in (I) C is for example formula (D), (E), (H) wherein A and B are independently selected from formulae (i) and (ii) and R2b and R6b, R2b and R6a, R3a and R5a, are for example selected from H, F, OMe and Me; R2b’ and R6b’, R2a’ and R6a’, R3a’, R5a’ are for example selected from H, OMe and Me; R1a and R1b are for example selected from hydroxy, -OSi(tri-(1-6C)alkyl), NR5C(=W) R4, formla (a), formula (b) wherein HET-1 is for example isoxazolyl and HET-2 is for example triazolyl or tetrazolyl. Methods for making compounds of the formula (I), compositions containing them and their use as antibacterial agents are also described.

OXAZOLIDINONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS

A compound of the formula (I), or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof: (I)wherein in (I) C is for example wherein A and B are independently selected from i) ii) and m is 1 or 2;R2b and R6b, R2a and R6a, R3a and R5a, are for example selected from H, F, OMe and Me;R2b' and R6b', R2a' and R6a', R3a', R5a' are for example selected from H, OMe and Me;R1a is for example optionally substituted (1-10C)alkyl;R1b is for example selected from NR5C(=W)R4, a) , or b) wherein HET-1 is for example isoxazolyl and HET-2 is for example triazolyl or tetrazolyl.Methods for making compounds of the formula (I), compositions containing them and their use as antibacterial agents are also described.